ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology

ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology Read MORE

LOS ANGELES, Oct. 14, 2019 /PRNewswire/ — ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda Pharmaceutical Company Limited…

Share:

Author: HEDGE

Executive Editor and Founder of HEDGEaccordingly.com. Hedge Was Founded in January 22, 2008. Learn more about HEDGEaccordingly